Breast Cancer Clinical Trial
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection
Confirmation of Triple Negative (TN) breast cancer by tissue biopsy
Life expectancy >16 weeks
KPS ≥ 70
Age ≥ 18 years
Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon
There is no limit on prior systemic therapies
Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study
Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment
Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation
Women who are pregnant or breastfeeding
Positive surgical margins
History of allergy or hypersensitivity to any of the study drugs or study drug components
Metastatic breast cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Clearwater Florida, 33756, United States More Info
Tampa Florida, 33612, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.